Equity · Healthcare
REGN
NASDAQRegeneron Pharmaceuticals (REGN)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for REGN to draw a line in its place.
- Market cap
- 98.6B USD
- P/E (TTM)
- 20.5
- Revenue, year to Dec 2025
- 14.3B USD
- EPS, diluted, year to Dec 2025
- 41.48 USD
- 52-week range
- 576.01 USD – 927.66 USD
- Avg volume
- 38.7K
as of Oct 30, 2026
Have Regeneron Pharmaceuticals (REGN) insiders bought or sold shares recently?
REGN has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 14 October 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 14 Oct 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Sell | 4,147 | 3.2M USD |
| 03 Sep 2026 | McCourt MarionEVP Commercial | Sell | 1,131 | 970K USD |
| 02 Sep 2026 | Guarini KathrynDirector | Sell | 400 | 340K USD |
| 02 Sep 2026 | McCourt MarionEVP Commercial | Sell | 1,215 | 1.0M USD |
| 10 Aug 2026 | Guarini KathrynDirector | Sell | 400 | 320K USD |
| 10 Aug 2026 | Zoghbi Huda YDirector | Sell | 800 | 640K USD |
| 02 Jul 2026 | RYAN ARTHUR FDirector | Sell | 200 | 130K USD |
| 01 May 2026 | RYAN ARTHUR FDirector | Sell | 100 | 71K USD |
| 01 Apr 2026 | RYAN ARTHUR FDirector | Sell | 100 | 78K USD |
| 02 Mar 2026 | RYAN ARTHUR FDirector | Sell | 100 | 79K USD |
| 19 Feb 2026 | Zoghbi Huda YDirector | Sell | 1,638 | 1.3M USD |
| 09 Feb 2026 | Pitofsky JasonSVP Controller | Sell | 2,036 | 1.6M USD |
| Sold | 14 open-market sales | 13,867 | $11.01M |
Showing the 12 most recent of 14 open-market trades in this window. The figures above count all of them.
17 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 13 Oct 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Option exercise | 17,000 | 6.5M USD |
| 13 Oct 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Tax withheld | 12,853 | 9.7M USD |
| 02 Sep 2026 | Guarini KathrynDirector | Option exercise | 400 | 288K USD |
| 19 Aug 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Option exercise | 12,282 | 4.7M USD |
| 19 Aug 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Tax withheld | 9,019 | 7.5M USD |
| 18 Aug 2026 | Fenimore Christopher R.EVP Finance CFO | Option exercise | 6,283 | 2.4M USD |
| 18 Aug 2026 | Fenimore Christopher R.EVP Finance CFO | Tax withheld | 4,599 | 3.7M USD |
| 10 Aug 2026 | Guarini KathrynDirector | Option exercise | 400 | 288K USD |
| 10 Aug 2026 | Zoghbi Huda YDirector | Option exercise | 800 | 301K USD |
| 19 Feb 2026 | Zoghbi Huda YDirector | Option exercise | 1,638 | 617K USD |
| 09 Feb 2026 | Pitofsky JasonSVP Controller | Option exercise | 1,000 | 492K USD |
| 07 Jan 2026 | Bassler Bonnie LDirector | Option exercise | 1,500 | 561K USD |
Showing the 12 most recent of 17 compensation filings in this window. The figures above count all of them.
Which funds hold Regeneron Pharmaceuticals (REGN)?
11 of the 45 institutional funds we track reported a Regeneron Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 1.7B USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 1,126,080 | 702.2M USD | −8.5% |
| Two Sigma Investments | Held (±25%) | 656,124 | 409.1M USD | −19.2% |
| Man Group | Added | 436,956 | 272.5M USD | +38.6% |
| Millennium Management | Added | 165,120 | 103.0M USD | +163.2% |
| Renaissance Technologies | Added | 148,222 | 92.4M USD | +121.9% |
| Citadel Advisors | Held (±25%) | 57,604 | 35.9M USD | +20.8% |
| Bridgewater Associates | Added | 51,333 | 32.0M USD | +125.9% |
| D. E. Shaw & Co. | Added | 38,477 | 24.0M USD | +69.3% |
| Marshall Wace | Added | 23,000 | 14.3M USD | +6,415.6% |
| Balyasny Asset Management | Added | 9,432 | 5.9M USD | +526.7% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Regeneron Pharmaceuticals (REGN)?
The most recent congressional trade disclosed in Regeneron Pharmaceuticals is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 15 May 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 15 May 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 24 days |
| 18 Nov 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 27 days |
| 15 May 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Purchase | 1K USD–15K USD | 25 days |
| 10 Apr 2025 | Byron Donaldshouse · Republican–FL | Sale | 1K USD–15K USD | 44 days |
| 08 Apr 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Sale | 1K USD–15K USD | 30 days |
| 07 Apr 2025 | Jefferson Shrevehouse · Republican–IN | Sale | 15K USD–50K USD | 31 days |
| 01 Apr 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 43 days |
| 25 Feb 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Sale | 1K USD–15K USD | 30 days |
Regeneron Pharmaceuticals (REGN) US federal contracts
US federal agencies committed 279.4M USD in contracts to Regeneron Pharmaceuticals (REGN) in fiscal 2026, the year to 30 Sep 2026.
USAspending.gov
| Fiscal year | Committed |
|---|---|
| Fiscal 2026 (Oct 2025 to Sep 2026) | 279.4M USD |
| Fiscal 2023 (Oct 2022 to Sep 2023) | 326.5M USD |
Contracts of US$100,000 or more signed since April 2022; the amount is what the government has committed so far, which grows when options are exercised. Defense Department contracts are published about 90 days after signing, so the latest year is still filling in.
What has been filed or recorded for Regeneron Pharmaceuticals (REGN)?
The filings we hold for Regeneron Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 18.45 USD | |
| 30 Sep 2026 | Financials | Total assets | 44.4B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 33.5B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 12.23 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 6.75 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 41.48 USD | |
| 31 Dec 2025 | Financials | Revenue | 14.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 4.5B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 41.48 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 13.62 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 12.81 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 7.27 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 38.34 USD |
Regeneron Pharmaceuticals (REGN): frequently asked questions
What is Regeneron Pharmaceuticals’ market cap?
Regeneron Pharmaceuticals is worth 98.6B USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Regeneron Pharmaceuticals’ P/E ratio?
Regeneron Pharmaceuticals has a price-to-earnings ratio of 20.5, as of 30 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Regeneron Pharmaceuticals’ revenue?
Regeneron Pharmaceuticals reported revenue of 14.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Regeneron Pharmaceuticals insiders bought or sold shares recently?
No Regeneron Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 14 Oct 2026 (SEC Form 4). See Insiders
Which funds own Regeneron Pharmaceuticals?
11 of the 45 funds we track reported a Regeneron Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Man Group. See Funds
Have members of Congress traded Regeneron Pharmaceuticals?
Yes. 37 trades in Regeneron Pharmaceuticals appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 15 May 2026, filed 8 Jun 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Regeneron Pharmaceuticals last report earnings?
Regeneron Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 18.45 USD; no next date is announced in SEC filings yet. See Filings
Does Regeneron Pharmaceuticals have government contracts?
Yes. US federal agencies committed 279.4M USD in contracts to it in fiscal 2026, the year to 30 Sep 2026 (USAspending.gov). See Contracts
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- USAspendingUSAspending.gov (U.S. Department of the Treasury), federal prime contract awards
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals